Opaleye Management’s AnaptysBio ANAB Stock Holding History

Opaleye Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-250,933	Closed	-$4.66M	–	42
2025 Q1	$4.66M	Buy	+250,933	New	+$4.19M	1.04%	21

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Opaleye Management's ANAB Position: Q2 2025 in Review

Opaleye Management sold out of AnaptysBio (ANAB) in Q2 2025, closing a stake of 250,933 shares — an estimated $4.66M sold.

Opaleye Management first reported a position in ANAB in Q1 2025 and held it in 1 quarter. The position peaked at $4.66M in Q1 2025. 147 funds tracked by Wall St. Rank hold ANAB as of Q2 2025.

Opaleye Management reported no remaining AnaptysBio position as of Q2 2025 after selling out during the quarter.
Opaleye Management sold 250,933 AnaptysBio shares in Q2 2025, an estimated $4.66M.
Opaleye Management first reported a position in AnaptysBio in Q1 2025 and held it in 1 quarter.
Opaleye Management's AnaptysBio position peaked at $4.66M in Q1 2025.
147 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2025.

Based on Opaleye Management's 13F filing for Q2 2025, filed 14 Aug 2025.